Physician profile
Zev Lagstein
NPI 1104873876
$6,932.75
in general payments reported to CMS, 2019-2025
18 companies · $497 in 2025
The $497 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,518 · 2020: $368 · 2021: $876 · 2022: $1,203 · 2023: $1,561 · 2024: $911 · 2025: $497.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,949 · Education: $19.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,949.29 |
| Education | $19.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,548.02 | 2019-2025 | Farxiga, Lokelma |
| Abbott Laboratories | $834.27 | 2023-2024 | Tacticath Ablation Catheter, Sensor Enabled, Aveir, Mitraclip |
| Boehringer Ingelheim Pharmaceuticals, INC. | $708.49 | 2021-2025 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $642.72 | 2019-2024 | Eliquis, Camzyos |
| Janssen Pharmaceuticals, INC | $582.12 | 2019-2024 | Xarelto |
| Pfizer INC. | $575.20 | 2019-2024 | |
| Actelion Pharmaceuticals US, INC. | $516.10 | 2019-2023 | Uptravi, Opsumit |
| Bayer Healthcare Pharmaceuticals INC. | $332.16 | 2021-2023 | |
| Novo Nordisk INC | $291.60 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Amarin Pharma, INC. | $279.25 | 2019-2021 | |
| Edwards Lifesciences Corporation | $172.45 | 2021 | |
| Novartis Pharmaceuticals Corporation | $144.05 | 2019-2025 | |
| Boston Scientific Corporation | $137.22 | 2022 | |
| Sanofi-Aventis U.S. LLC | $75.82 | 2021-2022 | |
| Philips North America LLC | $49.98 | 2022-2023 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $18.53 | 2019 | |
| Cvrx, INC. | $13.63 | 2024 | Barostim Neo System |
| Arbor Pharmaceuticals, INC. | $11.14 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Zev Lagstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.